GlassScriptPhysician profile
Sandra Marie Coleman
NPI 1003219700
$6,839.03
in general payments reported to CMS, 2019-2025
24 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,781 · 2023: $1,563 · 2024: $1,398 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,010 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,009.50 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,306.40 | 2022-2025 | |
| Corium, LLC | $817.66 | 2022-2025 | Azstarys |
| Validus Pharmaceuticals LLC | $816.95 | 2022-2025 | Equetro, Equetro, Raldesy |
| Supernus Pharmaceuticals, INC. | $767.17 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $672.35 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $298.81 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $287.60 | 2022-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $250.29 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $214.90 | 2022-2025 | Invega Sustenna, Spravato |
| Bausch Health US, LLC | $210.02 | 2022-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $180.33 | 2024-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $167.50 | 2022 | |
| Noven Therapeutics, LLC | $147.09 | 2023-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $147.04 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $142.83 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $113.80 | 2024-2025 | Relexxii |
| Lundbeck LLC | $113.20 | 2022-2024 | Rexulti |
| Novo Nordisk INC | $59.08 | 2025 | Wegovy |
| Vanda Pharmaceuticals INC. | $28.03 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $22.69 | 2024 | Quviviq |
| Neos Therapeutics, LP | $22.24 | 2022 | |
| Biogen, INC. | $20.68 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $16.50 | 2025 | Cobenfy |
| Avion Pharmaceuticals | $15.87 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.